Chimerix Investor Conference Presentation Deck

● Summary Integrated response analysis results RANO-HGG criteria assessed by dual reader BICR ORR 20% (95% CI: 10 -34%) Median DOR 11.2 months (95% CI: 3.8 - not reached) Median time to response 8.3 months (range 1.9 - 15.9) Disease control rate 40% (95% CI: 26 - 55%) PFS at 6 months 35% (95% CI: 21 - 49%); PFS at 12 months 30% (17-44) ● 22 ● ● ● ● RANO-LGG criteria assessed by dual reader BICR ORR 26% (95% CI: 15-40%) ● Overall survival ● ● 12 months: 57% (41-70%) 24 months: 35% (95% CI: 21 - 49%) ONC201 monotherapy exhibited apparent durable and clinically meaningful efficacy in recurrent H3 K27M- mutant DMG patients

View entire presentation